SDF-1α (stromal cell-derived factor 1α) induces cardiac fibroblasts, renal microvascular smooth muscle cells, and glomerular mesangial cells to proliferate, cause hypertrophy, and produce collagen

Journal of the American Heart Association

Volumn 6, Issue 11, 2017, Pages

  Jackson, Edwin K ^a   Zhang, Yumeng ^a   Gillespie, Delbert D ^a   Zhu, Xiao ^a   Cheng, Dongmei ^a   Jackson, Travis C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

C X C motif chemokine receptor 4; cardiac fibroblasts; Dipeptidyl peptidase 4; Fibroblasts; Glomerular mesangial cells; Hypertension; Kidney; Sitagliptin; Stromal cell derived factor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; COLLAGEN; DIPEPTIDYL PEPTIDASE IV; PHOSPHOLIPASE C; PROTEIN KINASE C; RECEPTOR FOR ACTIVATED C KINASE 1; STROMAL CELL DERIVED FACTOR 1ALPHA; CXCL12 PROTEIN, RAT; CXCR4 PROTEIN, RAT; RNA; STROMAL CELL DERIVED FACTOR 1;

ADULT; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SIZE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GLOMERULAR MESANGIAL CELL; HEART FIBROBLAST; MALE; MESANGIUM CELL; NONHUMAN; PREGLOMERULAR VASCULAR SMOOTH MUSCLE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE CELL; WISTAR KYOTO RAT; ANIMAL; BIOSYNTHESIS; CARDIAC MUSCLE; CELL CULTURE; DISEASE MODEL; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; GLOMERULUS; HYPERTROPHIC CARDIOMYOPATHY; KIDNEY ARTERY; METABOLISM; MICROVASCULATURE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHY, HYPERTROPHIC; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL12; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROBLASTS; GENE EXPRESSION REGULATION; KIDNEY GLOMERULUS; MALE; MESANGIAL CELLS; MICROVESSELS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CXCR4; RENAL ARTERY; RNA;

EID: 85034784633     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.117.007253     Document Type: Article

References (40)

1. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept. 2005;128:159-165
2. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci. 2005;108:277-292
3. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24
4. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35:992-1019
5. Berglund MM, Hipskind PA, Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med. 2003;228:217-244
6. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev. 1998;50:143-150
7. Jackson EK, Kochanek SJ, Gillespie DG. Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. Hypertension. 2012;60:757-764
8. 1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4. Am J Physiol Heart Circ Physiol. 2015;309:H1528-H1542
9. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 2005;45:657-687
10. Dubey RK, Jackson EK, Rupprecht HD, Sterzel RB. Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Curr Opin Nephrol Hypertens. 1997;6:88-105
11. Wang W, Choi BK, Li W, Lao Z, Lee AY, Souza SC, Yates NA, Kowalski T, Pocai A, Cohen LH. Quantification of intact and truncated stromal cell-derived factor-1a in circulation by immunoaffinity enrichment and tandem mass spectrometry. J Am Soc Mass Spectrom. 2014;25:614-625
12. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta. 2007;1768:952-963
13. Zhu X, Jackson EK. RACK1 regulates angiotensin II-induced contractions of SHR preglomerular vascular smooth muscle cells. Am J Physiol Renal Physiol. 2017;312:F565-F576
14. Inoue T, Mi Z, Gillespie DG, Jackson EK. Cyclooxygenase inhibition reveals synergistic action of vasoconstrictors on mesangial cell growth. Eur J Pharmacol. 1998;361:285-291
15. 1-36 in SHR vs. WKY preglomerular vascular smooth muscle cells. Am J Physiol Renal Physiol. 2013;304:F770-F780
16. Jackson EK, Menshikova EV, Mi Z, Verrier JD, Bansal R, Janesko-Feldman K, Jackson TC, Kochanek PM. Renal 20, 30-cyclic nucleotide 30-phosphodiesterase is an important determinant of AKI severity after ischemia-reperfusion. J Am Soc Nephrol. 2016;27:2069-2081
17. Jie W, Wang X, Zhang Y, Guo J, Kuang D, Zhu P, Wang G, Ao Q. SDF-1a/CXCR4 axis is involved in glucose-potentiated proliferation and chemotaxis in rat vascular smooth muscle cells. Int J Exp Pathol. 2010;91:436-444
18. Pan CH, Chen CW, Sheu MJ, Wu CH. Salvianolic acid B inhibits SDF-1astimulated cell proliferation and migration of vascular smooth muscle cells by suppressing CXCR4 receptor. Vascul Pharmacol. 2012;56:98-105
19. Shao S, Cai W, Sheng J, Yin L. Role of SDF-1 and Wnt signaling pathway in the myocardial fibrosis of hypertensive rats. Am J Transl Res. 2015;7:1345-1356
20. Wang ER, Jarrah AA, Benard L, Chen J, Schwarzkopf M, Hadri L, Tarzami ST. Deletion of CXCR4 in cardiomyocytes exacerbates cardiac dysfunction following isoproterenol administration. Gene Ther. 2014;21:496-506
21. Chu P-Y, Zatta A, Kiriazis H, Chin-Dusting J, Du X-J, Marshall T, Kaye DM. CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ Heart Fail. 2011;4:651-658
22. Chu PY, Walder K, Horlock D, Williams D, Nelson E, Byrne M, Jandeleit-Dahm K, Zimmet P, Kaye DM. CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis. PLoS One. 2015;10:e0133616
23. Zuk A, Gershenovich M, Ivanova Y, MacFarland RT, Fricker SP, Ledbetter S. CXCR4 antagonism as a therapeutic approach to prevent acute kidney injury. Am J Physiol Renal Physiol. 2014;307:F783-F797
24. Yuan A, Lee Y, Choi U, Moeckel G, Karihaloo A. Chemokine receptor Cxcr4 contributes to kidney fibrosis via multiple effectors. Am J Physiol Renal Physiol. 2015;308:F459-F472
25. Kazakov A, Hall R, Jagoda P, Bachelier K, Muller-Best P, Semenov A, Lammert F, Bohm M, Laufs U. Inhibition of endothelial nitric oxide synthase induces and enhances myocardial fibrosis. Cardiovasc Res. 2013;100:211-221
26. Sayyed SG, Hagele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D, Klussmann S, Anders HJ. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia. 2009;52:2445-2454
27. Schober A, Knarren S, Lietz M, Lin EA, Weber C. Crucial role of stromal cellderived factor-1a in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation. 2003;108:2491-2497
28. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Mopps B, Mericskay M, Gierschik P, Biessen EA, Weber C. SDF-1a/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res. 2005;96:784-791
29. Chu PY, Mariani J, Finch S, McMullen JR, Sadoshima J, Marshall T, Kaye DM. Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am J Pathol. 2010;176:1735-1742
30. Subramanian S, Liu C, Aviv A, Ho JE, Courchesne P, Muntendam P, Larson MG, Cheng S, Wang TJ, Mehta NN, Levy D. Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. Arterioscler Thromb Vasc Biol. 2014;34:2100-2105
31. Zuern CS, Walker B, Sauter M, Schaub M, Chatterjee M, Mueller K, Rath D, Vogel S, Tegtmeyer R, Seizer P, Geisler T, Kandolf R, Lang F, Klingel K, Gawaz M, Borst O. Endomyocardial expression of SDF-1 predicts mortality in patients with suspected myocarditis. Clin Res Cardiol. 2015;104:1033-1043
32. Plosker GL. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74:223-242
33. Jackson EK. Context-dependent effects of dipeptidyl peptidase 4 inhibitors. Curr Opin Nephrol Hypertens. 2017;26:83-90
34. Shi S, Koya D, Kanasaki K. Dipeptidyl peptidase-4 and kidney fibrosis in diabetes. Fibrogenesis Tissue Repair. 2016;9:1
35. Bando YK, Murohara T. Heart failure as a comorbidity of diabetes: role of dipeptidyl peptidase 4. J Atheroscler Thromb. 2016;23:147-154
36. Fadini GP, Albiero M, Avogaro A. Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence. Vascul Pharmacol. 2015;73:1-3
37. Chen S, Spiegelberg BD, Lin F, Dell EJ, HammHE. Interaction of Gbetagammawith RACK1 and other WD40 repeat proteins. J Mol Cell Cardiol. 2004;37:399-406
38. Li JJ, Xie D. RACK1, a versatile hub in cancer. Oncogene. 2015;34:1890-1898
39. McCahill A, Warwicker J, Bolger GB, Houslay MD, Yarwood SJ. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol Pharmacol. 2002;62:1261-1273
40. Sklan EH, Podoly E, Soreq H. RACK1 has the nerve to act: structure meets function in the nervous system. Prog Neurobiol. 2006;78:117-134